Introduction {#sec0005}
============

The current SARS-CoV-2 pandemic is overwhelming health-care systems worldwide. Resource constraints have large undermined the effective implementation of preventive and therapeutic measures and protection of healthcare workers with proper equipment in some settings. Regarding diagnostic tests, the shortage of real-time polymerase chain reaction (PCR) specific reagents has led many centers to perform diagnosis of suspected COVID-19 disease based on clinical and radiological data, also considering the low-to-moderate rate of false negative tests.[@bib0055] Even though this may seem practical in the current context, it might lead to over-diagnosis of SARS-CoV-2 infection and to overlook other causes of respiratory infections that require specific treatment.

*Streptococcus pneumoniae* is the first cause of community-acquired pneumonia (CAP). The burden of pneumococcal disease in the community is reflected by the high mortality rate associated with the invasive form of infection that is up to 10--36% and affects predominantly elderly, chronic and immunocompromised patients.[@bib0060] Diagnosis of pneumococcal infection is usually suspected on clinical grounds and confirmed by isolation of the bacteria in cultures (blood or sputum) or detection of the C-polysaccharide antigen in urine. The radiological appearance is usually that of a consolidative lobar pneumonia. However, it can also present with bilateral infiltrates, including an interstitial pattern. COVID-19 most common radiological patterns include interstitial infiltrates, either unilateral or bilateral, but it can also present as a consolidative pneumonia.[@bib0065] This can lead to misdiagnosis of pneumococcal pneumonia if not suspected in the context of COVID-19 pandemic.

Nonetheless, concomitant or secondary bacterial infection has been scarcely and irregularly reported (4.8--15%) in the larger series of COVID-19 published to date.[@bib0070], [@bib0075] Meanwhile, although clinical guidelines recommend empirical antibacterial therapy in critically ill patients with elevated inflammatory parameters,[@bib0080] there is no clear guidance on the screening of *S. pneumoniae* and other common bacterial causative agents of respiratory infection during the pandemic.

We report 5 cases of COVID-19 in whom urinary antigen screening revealed *a posteriori* the coexistence of pneumococcal infection.

Case series {#sec0010}
===========

The characteristics of the 5 patients are shown in [Table 1](#tbl0005){ref-type="table"} . Median age was 56 (IQR 44--79), and 3 (60%) were females. Hypertension and diabetes was present in 40% of cases respectively, while there were no cases of diabetes or former/current smoking habit. The main symptoms leading to consultation were fever, cough and dyspnea, with diarrhea, arthromyalgia and dysgeusia being less common. SARS-CoV-2 infection was confirmed in 3 cases by means of PCR-positive swab, while in 2 cases was presumed due to typical clinical presentation, radiological appearance and epidemiological criteria (contact with a positive person). The pneumococcal infection was diagnosed by positive detection of the pneumococcal C-polysaccharide antigen in urine sample in all cases.Table 1Clinical, laboratory and radiological characteristics of patients coinfected by SARS-2-CoV and *Streptococcus pneumoniae*.Table 1Patient12345*Age*8638657944*Sex*MaleFemaleMaleFemaleFemale  *Days from symptoms onset* to hospital admission5413145 to SARS-CoV-2 swab5N/A13N/A4 to *S. pneumoniae* detection6516155  *Diabetes*YesNoNoNoYes*Hypertension (treatment)*Yes\
(ARBs)NoNoYes\
(ARBs, diuretic)No*Comorbidities*Ischemic Heart Disease\
Aortic Stenosis\
CKDNoneDepressionCKD\
Chronic anemiaObesity\
Asthma*Symptoms*Fever\
Cough\
DyspneaFever\
Cough\
Dyspnea\
ArthromyalgiaFever\
Cough\
Dyspnea\
Diarrhea\
Fever\
Cough\
Diarrhea\
ArthromyalgiaFever\
Cough\
Hyposmia\
Disgeusia\
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*Treatment COVID-19* Lopinavir/RitonavirYes (2)Yes (2)Yes (2)Yes (7)Yes (2) HydroxycloroquineYes (2)Yes (6)Yes (13)Yes (5)Yes (10) AzithromycinYes (4)Yes (4)Yes (5)Yes (5)Yes (5) OtherTocilizumab\
AnakinraNoneNoneTocilizumabNone 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Chest X-ray revealed bilateral interstitial infiltrates in 3 cases, and bilateral consolidative infiltrate and unilateral consolidative infiltrate in one case each ([Fig. 1](#fig0005){ref-type="fig"} ). All but one case received low-flux oxygen during the hospital stay and none presented circulatory shock, acute respiratory distress syndrome or pulmonary embolism.Fig. 1Chest X-ray in our series show bilateral infiltrates with an interstitial pattern in patients 2, 3 and 5 (image b, c, e) and a more consolidative pattern in patient 4 (image d). In patient 1, the appearance was that of a lobar consolidative pneumonia (image a). Subsequent CT scan of this patient (image f) also revealed ground-glass opacities suggesting organizing pneumonia.

The local clinical protocol for treatment of COVID-infection is based on lopinavir/ritonavir 200/50 mg two pills bid for one week, hydroxycloroquine 200 mg bid for six days after a loading dose of 400 mg bid for 1 day and azithromycin 250 mg daily for 4 days after a single loading dose of 500 mg. Empirical antibiotic treatment was started when procalcitonin levels were elevated according to the local protocol. Treatment for *S. pneumoniae* included ceftriaxone 1 g daily. In patient 1 it was upgraded to ceftaroline 600 mg bid and in the case of patient 4 was associated with teicoplanine 6 mg/kg for three doses followed by 6 mg/kg daily. Upon discharge, patients 2 and 5 were switched to oral cefixime 400 mg daily and patient 4 to oral levofloxacin 500 mg daily.

In three cases, clinical course was complicated by late inflammatory response consisting in worsening dyspnea, increase in oxygen requirement, radiological progression and increase in CRP. Patients 1, 3 and 4 received a single dose of tocilizumab 400 mg and patient number 1 also received 2 doses of 200 mg of anakinra. In that case, a thorax CT-scan was also performed, revealing bilateral ground glass opacities along with a pattern suggestive of organizing pneumonia ([Fig. 1](#fig0005){ref-type="fig"}f), thus a 30-day course of oral prednisone 30 mg was started. Subsequent evolution was satisfactory and all patients were discharged from the hospital, two of them at home and three at a medicalized hotel for recovery. Remarkably, patient 1 and 4 were vaccinated against *S. pneumoniae* with 23-valent vaccine in 2007 and 2008.

All five patients provided either written or oral informed consent following the procedure established by our institution Ethical Board during the state of infectious disease exceptionality.

Discussion {#sec0015}
==========

*S. pneumoniae* is the leading cause of CAP and affects predominantly frail populations, being the major risk factors age, diabetes, toxic habits (smoking and alcoholism), chronic pulmonary disease and immunodeficiency states. Pneumococcal infection has seasonal and latitude variations, being more common in winter and in countries with temperate-to-cold climate.[@bib0085] The radiological appearance is classically thought to be unilateral and consolidative. However, in many cases, it appears to be bilateral and assumes an interstitial pattern[@bib0090]; this may generate doubts when performing differential diagnosis with other causes of pneumoniae, such as the actual COVID-19 pandemic. Thus, radiological criteria *per se* are not sufficient to confirm or rule out pneumococcal infection and there can be a substantial overlap with COVID-19 clinical presentation, therefore highlighting the relevance of microbiological confirmation of SARS-CoV-2 infection in these cases. PCR for SARS-2-CoV infection is overall highly sensitive, even though several pre-analytical issues and during early phases of the infection can yield false-negative results.[@bib0095] Regarding confirmation of *S. pneumoniae* infection, sputum culture is limited by very low sensitivity. On the contrary, detection of the pneumococcal C-polysaccharide antigen in urine is a fast mean for screening and diagnosis with a sensitivity and specificity as high as 75 and 95%, respectively.[@bib0100]

In our series of 5 patients, 3 proved to be positive at swab PCR test for SARS-CoV-2 infection, while in 2 cases the test was omitted due to suggestive radiological appearance ([Fig. 1](#fig0005){ref-type="fig"}) along with typical laboratory findings and epidemiological criteria. According to the local protocol, these cases were promptly isolated and treatment for COVID-19 was started with lopinavir/ritonavir, hydroxycloroquine and azithromycin. However, subsequent testing proved that patients were also infected with *S. pneumoniae* by detection of the C-polysaccharide antigen in urine, and thus antibiotic treatment was started. Remarkably, procalcitonin was not elevated in all cases, thus suggesting that this should not be the only parameter used to decide further microbiological test to rule out bacterial infection.

With the present report we would like to highlight that common causes of respiratory infection should not be overlooked and that coinfection of SARS-2-CoV with other pathogens should be bear in mind. In case of coinfection with *S. pneumoniae*, diagnostic and therapeutic challenges may arise, especially when anti-inflammatory drugs are used to control the excessive inflammatory response associated with SARS-2-CoV. Given the expected persistence of the current pandemic in the next months, vaccination against *S. pneumoniae* infection seems a reasonable option especially for high-risk patients. Meanwhile, specific antibiotic coverage and hospitalization besides antiviral treatment are advisable in patients with suspected or confirmed COVID-19 and pneumococcal co-infection.
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